RIPTAC
Johnson & Johnson’s $3 Billion Bet: Halda Therapeutics Acquisition Ushers in Next-Gen Cancer Drug Era
Johnson & Johnson’s acquisition of Halda Therapeutics for $3.05 billion signals a pivotal moment in cancer treatment innovation, spotlighting the promise of RIPTAC™ and targeted protein degradation technologies.